Rodin Therapeutics

Rodin Therapeutics was a biopharmaceutical company focused on developing therapies for synaptopathies, a group of neurological disorders characterized by the loss of synaptic function. The company was co-founded in 2013 by Atlas Venture, a biotech-focused venture capital firm, and Proteros Biostructures. Adam J. Rosenberg, a seasoned entrepreneur with a background in law and extensive experience leading biotech startups like Teleos Therapeutics and Link Medicine Corporation, was appointed CEO in 2015. His leadership guided the company through critical funding stages and its ultimate acquisition.

The company's core business was centered on discovering and developing small molecule drugs that could penetrate the brain and selectively modulate the activity of histone deacetylase (HDAC) complexes. Specifically, Rodin targeted the HDAC-CoREST (Co-repressor of Repressor Element-1 Silencing Transcription Factor) complex. The scientific rationale was that inhibiting this specific complex could reactivate neuronal gene expression, strengthen existing synapses, and promote the creation of new ones, thereby addressing the synaptic loss that is a key correlate of cognitive decline in many neurodegenerative diseases. This approach was designed to overcome the hematological toxicity issues associated with older, less selective HDAC inhibitors, making it a more viable strategy for chronic treatment of conditions like Alzheimer's, Parkinson's, and Huntington's disease. The company's business model was rooted in capital-efficient research and development, advancing its lead candidates into clinical trials with the aim of either commercializing them or partnering with larger pharmaceutical companies. This strategy culminated in a significant milestone when Rodin was acquired by Alkermes plc in November 2019. The deal involved an upfront payment of $100 million, with the potential for an additional $850 million in milestone payments, validating Rodin's focused approach to developing treatments for CNS disorders.

Rodin's primary therapeutic candidate, RDN-929, was a brain-penetrant, complex-selective HDAC inhibitor. Preclinical studies demonstrated its ability to increase synaptic density and improve long-term potentiation in mouse models. The compound successfully entered Phase 1 clinical trials in late 2018, where it was found to be safe, well-tolerated, and active in engaging its target without the typical hematological side effects of other drugs in its class. This achievement was a crucial step, demonstrating the potential of its selective inhibition platform. The company's strategy also included the use of advanced neuroimaging biomarkers, such as the SV2A PET ligand, to monitor synaptic density in patients' brains in real-time, providing a more direct measure of therapeutic effect. Keywords: Rodin Therapeutics, synaptopathies, neurodegenerative disorders, HDAC inhibitors, CoREST complex, synaptic plasticity, Alkermes acquisition, Adam J. Rosenberg, Atlas Venture, Proteros Biostructures, small molecule therapeutics, CNS disorders, Alzheimer's disease treatment, Parkinson's disease research, RDN-929, epigenetic regulation, neuropharmacology, biotech M&A, venture capital, clinical trials, synaptic resilience, neuronal health, frontotemporal dementia